SCHEMBL92960

SCHEMBL92960

Cc1ccsc1-c1ccc(-c2ccc(-c3sc(-c4cc(C)c(-c5ccc(-c6ccc(-c7sccc7C)s6)s5)s4)cc3C)s2)s1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 8/20 0.42
ESR2 Q92731 5/20 0.37
ESR1 P03372 4/20 0.37
CYP3A4 P08684 3/20 0.35
CYP2C19 P33261 3/20 0.35
CYP2B6 P20813 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2E1 P05181 1/20 0.35
NISCH Q9Y2I1 1/20 0.34
HSD17B1 P14061 1/20 0.34
HSD17B2 P37059 1/20 0.34
PGR P06401 2/20 0.33
KDM4E B2RXH2 1/20 0.33
CYP1A2 P05177 1/20 0.33
HTT P42858 1/20 0.33
RECQL P46063 1/20 0.33
RIPK2 O43353 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10820285 1.00 CYP2A6 (0.42) CYP2A6ESR2ESR1CYP3A4CYP2C19
SCHEMBL92955 1.00 CYP2A6 (0.42) CYP2A6ESR2ESR1CYP3A4CYP2C19
SCHEMBL18027618 0.96 CYP2A6 (0.42) CYP2A6ESR2ESR1CYP3A4CYP2C19
SCHEMBL13082012 0.94 CYP2A6 (0.43) CYP2A6ESR2ESR1CYP3A4CYP2C19
SCHEMBL10820283 0.91 ESR1 (0.49) CYP2A6ESR2ESR1CYP3A4CYP2C19
SCHEMBL29767746 0.89 DPP4 (0.35) CYP2A6ESR2ESR1PGR
SCHEMBL29767749 0.89 DPP4 (0.35) CYP2A6ESR2ESR1PGR
SCHEMBL12445155 0.88 CYP2A6 (0.45) CYP2A6ESR2CYP3A4CYP2C19CYP2B6
SCHEMBL19165108 0.88 CYP2A6 (0.45) CYP2A6ESR2CYP3A4CYP2C19CYP2B6
SCHEMBL92957 0.88 CYP2A6 (0.35) CYP2A6ESR2ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222073-B2 Fabricating TFT having fluorocarbon-containing layer XEROX CORPORATION (US) 2012-07-17 US disclosed
US-8129497-B2 Organic thin film transistor KONICA MINOLTA HOLDINGS, INC. (JP) 2012-03-06 US disclosed
US-8003435-B2 Method of manufacturing organic film transistor KONICA MINOLTA HOLDINGS, INC. (JP) 2011-08-23 US disclosed
US-7834199-B2 Small molecular thiophene compound having divalent linkage XEROX CORPORATION (US) 2010-11-16 US disclosed
US-7816263-B2 Method for manufacturing thin film transistor KONICA MINOLTA HOLDINGS, INC. (JP) 2010-10-19 US disclosed
US-20100178727-A1 METHOD OF MANUFACTURING ORGANIC FILM TRANSISTOR KONICA MINOLTA HOLDINGS, INC. (JP) 2010-07-15 US disclosed
US-20100105161-A1 Method for Manufacturing Thin Film Transistor KONICA MINOLTA HOLDINGS, INC. (JP) 2010-04-29 US disclosed
US-7700787-B2 Small molecular thiophene compound XEROX CORPORATION (US) 2010-04-20 US disclosed
US-20100090199-A1 Organic Semiconductor Film Forming Method, Organic Semiconductor Film and Organic Thin Film Transistor KONICA MINOLTA HOLDINGS ,INC. (JP) 2010-04-15 US disclosed
US-20090114908-A1 ORGANIC SEMICONDUCTOR THIN FILM, ORGANIC THIN FILM TRANSISTOR AND METHOD OF MANUFACTURING ORGANIC THIN FILM TRANSISTOR KONICA MINOLTA HOLDINGS, INC. (JP) 2009-05-07 US disclosed
US-20090111210-A1 Method for Organic Semiconductor Material Thin-Film Formation and Process for Producing Organic Thin Film Transistor KONICA MINOLTA HOLDINGS, INC. (JP) 2009-04-30 US disclosed
US-20080108833-A1 SMALL MOLECULAR THIOPHENE COMPOUND XEROX CORPORATION (US) 2008-05-08 US disclosed
US-20080108834-A1 SMALL MOLECULAR THIOPHENE COMPOUND HAVING DIVALENT LINKAGE XEROX CORPORATION (US) 2008-05-08 US disclosed
US-20080048181-A1 Organic Semiconductor Thin Film, Organic Semiconductor Device, Organic Thin Film Transistor and Organic Electronic Luminescence Element KONICA MINOLTA HOLDINGS, INC. (JP) 2008-02-28 US disclosed
US-20070243658-A1 Production method of crystalline organic semiconductor thin film, organic semiconductor thin film, electronic device, and thin film transistor KONICA MINOLTA HOLDINGS, INC. (JP) 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108834-A1 SMALL MOLECULAR THIOPHENE COMPOUND HAVING DIVALENT LINKAGE TST, AS3MT, TH CYP2A6 490/4885ESR2 1934/4885ESR1 969/4885
US-20080108833-A1 SMALL MOLECULAR THIOPHENE COMPOUND TST, ABCG2, TPMT CYP2A6 221/4885ESR2 1789/4885ESR1 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.